Compound overview

Sermorelin: What It Is and What It Was Approved For

Sermorelin is unusual among the peptides sold for anti-aging: it was genuinely an FDA-approved medicine, twice over. Reading what those approvals actually covered is the fastest way to understand what is being sold today.

  • 1990 and 1997The years the two GEREF products were approved by the FDA
  • ChildrenWho the treatment approval was for: growth failure from growth hormone deficiency
  • 2009When the FDA withdrew approval of both applications, at the maker’s request
  • Not listedOn the FDA risk list that BPC-157, ipamorelin and CJC-1295 appear on

Regulatory status

There is no FDA-approved sermorelin product in the United States. Both approvals were withdrawn in 2009 at the manufacturer’s request, and the FDA has confirmed this was not for reasons of safety or effectiveness. What is dispensed today is a compounded prescription medicine, which is not FDA-approved and is not reviewed before dispensing.

The short version

Sermorelin was approved by the FDA under two separate applications: one to treat growth failure in children, and one as a diagnostic agent for testing pituitary function. It was never approved for adults seeking better sleep, more muscle, or slower ageing. Those are the uses it is sold for now.

Both approvals were withdrawn in 2009 after the manufacturer stopped making it. The FDA later confirmed, formally and in writing, that the withdrawal had nothing to do with safety or effectiveness — a finding that genuinely distinguishes sermorelin from most compounds in this market, and one worth understanding precisely rather than in the loose form it usually takes.

What sermorelin is

Sermorelin is a shortened synthetic copy of growth hormone-releasing hormone, the signal the brain sends to the pituitary gland telling it to release growth hormone. The body’s own version is 44 amino acids long; sermorelin reproduces the first 29, which is the portion that carries the biological activity.

That mechanism is the reason it gets discussed differently from growth hormone itself. Injected growth hormone supplies the hormone directly, overriding the body’s own control. Sermorelin instead prompts the pituitary to produce its own, which means the output stays subject to the feedback loops that normally regulate it. Whether that difference matters clinically in adults is a separate question, and not one the approvals answer.

Worth knowing

A pituitary that is being asked to work does need to be capable of working. The mechanism that makes sermorelin interesting also makes it dependent on the gland it is signalling — which is precisely why one of its two approvals was as a test of whether that gland functions.

What it was actually approved for

This is the part most coverage skips, and it is a matter of public record rather than interpretation. Both products were held by EMD Serono and sold under the brand name GEREF. The FDA’s own description of each indication reads as follows.

  • The diagnostic product, approved 28 December 1990 under NDA 19-863. Indicated, in the agency’s words, “for evaluating the ability of the somatotroph of the pituitary gland to secrete growth hormone.” This is a test, given once to find out whether a gland responds. It is not a treatment for anything.
  • The treatment product, approved 26 September 1997 under NDA 20-443. Indicated “for the treatment of idiopathic growth hormone deficiency (GHD) in children with growth failure.” A paediatric indication, for children who are not growing, with a diagnosed deficiency.

The distance worth measuring

Neither approval covered adults. Neither covered ageing, body composition, sleep, recovery, or wellbeing. The entire market that exists for sermorelin today sits outside both indications it was ever approved for.

That is not automatically damning. Prescribing outside an approved indication is legal, common, and often well supported by evidence gathered after approval. But it does relocate the burden: the approvals cannot be cited as evidence for the modern use, because they were not about it. Anyone offering “FDA-approved” as a reason to take sermorelin for ageing is describing a different drug being used for a different purpose in different people.

Why it left the market, and what the FDA said about it

EMD Serono notified the FDA in July 2008 that the diagnostic product was being discontinued, and in December 2008 that the treatment product was too. The company asked for both applications to be withdrawn. The FDA announced the withdrawal of both in May 2009, effective 18 June that year.

In October 2012 a petitioner asked the agency to determine formally whether the withdrawal had been for reasons of safety or effectiveness. The FDA published its answer in March 2013, and the reasoning is more thorough than the conclusion alone suggests.

What the FDA determined

“We have also independently evaluated relevant literature and data for possible postmarketing adverse events for both GEREF products. We have reviewed the available evidence and determined that both GEREF products were not withdrawn from sale for reasons of safety or effectiveness.”

The agency did not simply take the company’s word for it. It reviewed its own files, and it went looking through the literature for post-marketing adverse events. Finding none that explained the withdrawal, it concluded the products left the market for commercial reasons. For a compound sold in this corner of the market, that is a meaningfully clean regulatory record.

What that determination did not do

The 2013 finding is quoted widely as though it authorised the sermorelin market. It did not, and the document is explicit about what it was for.

Read the stated purpose

“This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for GEREF (Sermorelin Acetate) injection … if all other legal and regulatory requirements are met.”

An abbreviated new drug application is how a generic version gets approved. The determination cleared a path for someone to bring an approved generic sermorelin to market. It says nothing about compounding, which is a different legal route with its own separate requirements, and to our knowledge no generic has since been approved.

So the honest summary of sermorelin’s status is narrower than the marketing version: it once had two approvals, those approvals were withdrawn for commercial reasons the FDA verified, the door was formally opened for a generic, and nobody walked through it. There is no FDA-approved sermorelin product available in the United States today. What is dispensed is compounded.

How sermorelin differs from the peptides on the FDA risk list

Sermorelin is often grouped with the growth hormone peptides sold alongside it, and there is a checkable difference between them. The FDA maintains a list of bulk drug substances it says may present significant safety risks in compounding. Ipamorelin, CJC-1295 and BPC-157 are all on it. Sermorelin is not.

That is a real distinction and it should be stated plainly, because this site spends most of its time being sceptical and the sceptical position here is narrower than usual. Sermorelin has been through the approval process. Its safety record was reviewed by the agency as recently as 2013. It is prescribed by clinicians rather than sold as a research chemical labelled not for human consumption.

Worth knowing

Absence from a risk list is not the same as presence on an approved list. It means the FDA has not flagged sermorelin as presenting significant safety risks in compounding — not that it has endorsed the way it is currently used.

The questions that remain are about the modern use rather than the molecule: whether raising growth hormone output benefits healthy adults, what the long-term effects of doing so are, and what a compounded product actually contains. Those are covered on the pages below as we publish them.

What this site will not tell you about sermorelin

  • How much to take. Sermorelin is a prescription medicine and the amount is a decision for the clinician prescribing it, working from the individual in front of them.
  • How to reconstitute or inject it, or when in the day to do so.
  • Where to buy it without a prescription. Anything sold that way is outside the compounding route described above, and is a different product with none of the protections.
  • Whether it is right for you. We do not employ clinicians and we have never met you.

Sources and method

  • The approvals, the indications and the withdrawal. Determination That GEREF (Sermorelin Acetate) Injection … Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness, FDA notice published in the Federal Register, 4 March 2013 (78 FR 14095). Every date, NDA number, indication and quotation on this page is taken from that document.
  • The withdrawal of approval. Announced by the FDA in the Federal Register of 19 May 2009 (74 FR 23407), effective 18 June 2009, following EMD Serono’s requests of July and December 2008.
  • The risk-list comparison. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA. We searched that page for sermorelin and did not find it; ipamorelin, CJC-1295 and BPC-157 all appear on it.
  • What we could not verify. We have not established which specific legal pathway supports the compounding of sermorelin today, and we do not assert that it is or is not permitted — that is a determination for the FDA and for the pharmacies involved. We have not confirmed whether any ANDA has been approved since 2013 and state only that we are not aware of one. We have not reviewed the original GEREF prescribing information, so this page does not describe its safety profile; that will be covered separately.
  • Method. Regulatory history is read from the primary Federal Register record rather than from secondary summaries of it, several of which describe the 2013 determination as authorising compounding. It does not say that, and the difference matters.

BPC-157 overview →   Regulatory tracker →   How we source and verify →

Federal Register and FDA sources checked 30 August 2026. We recheck this page if an ANDA is approved or the FDA acts on sermorelin.